In contrast, similarly to what has been described in other tumor types, the treatment of HCC cells with these drugs led to eIF4A2 upregulation, which is considered a compensatory response to marked eIF4A1 suppression. This evidence concerns the gene EIF4A1 and hepatocellular carcinoma.